



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	387611	Youthful
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Locako	
<b>Postal Address</b>	178 Edgecliff Road, Woollahra, NSW, 2025 Australia	
<b>ARTG Start Date</b>	28/04/2022	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Youthful

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	28/04/2022
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

Helps reduce/decrease free radical damage to body cells  
Maintain/support hair growth  
Maintain/support hair health  
Enhance/improve/promote/increase hair strength/thickness  
Aid/assist nail growth  
Maintain/support nail health/strength/thickness  
Enhance/improve/promote/increase nail health/strength/thickness  
Helps enhance/promote skin health  
Helps enhance/improve skin elasticity  
Helps enhance/promote skin regeneration  
Maintain/support skin repair/healing/regeneration

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. If symptoms persist, seek the advice of a healthcare professional.

#### Additional Product information

#### Pack Size/Poison information

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

Public Summary



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

ascorbic acid	250 mg
Biotin	150 microgram
nicotinamide	75 mg
Terminalia ferdinandiana fruit flesh Powder	50 mg
zinc glycinate monohydrate	5 mg
Equivalent: zinc	1.41 mg

**Other Ingredients (Excipients)**

calcium hydrogen phosphate dihydrate  
colloidal anhydrous silica  
hypromellose  
magnesium stearate  
microcrystalline cellulose  
potable water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary